These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35621628)

  • 21. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
    Ma X; Guo Z; Wei X; Zhao G; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao L; Yuan Z; Wang P; Pang Q; Yan C; Zhang W
    Front Immunol; 2021; 12():786429. PubMed ID: 35046943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma.
    Shiraishi K; Takeyasu Y; Yamamoto S; Oshima K; Imazeki H; Hirano H; Okita N; Shoji H; Honma Y; Iwasa S; Takasima A; Kato K
    Esophagus; 2024 Oct; 21(4):539-545. PubMed ID: 39222157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
    Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
    Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
    BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study.
    Bai M; Wang WX; Deng T; Duan JJ; Ba Y
    Drug Des Devel Ther; 2024; 18():4135-4151. PubMed ID: 39308693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
    Yu N; Cheng G; Li J; Liang J; Zhang T; Deng L; Liu W; Wang J; Zhai Y; Wang W; Xiao Z; Zhou Z; Chen D; Feng Q; Bi N; Wang X
    Curr Cancer Drug Targets; 2023; 23(8):653-662. PubMed ID: 36924100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Effect of Radiotherapy Combined with Chemotherapy for Non-Surgical Treatment of the Esophageal Squamous Cell Carcinoma.
    Chen H; Zhou L; Yang Y; Yang L; Chen L
    Med Sci Monit; 2018 Jun; 24():4183-4191. PubMed ID: 29915168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Kim JH; Ahn B; Hong SM; Jung HY; Kim DH; Choi KD; Ahn JY; Lee JH; Na HK; Kim JH; Kim YH; Kim HR; Lee HJ; Kim SB; Park SR
    Cancer Res Treat; 2022 Apr; 54(2):505-516. PubMed ID: 34176250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
    Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
    Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
    Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
    Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
    Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
    [No Abstract]   [Full Text] [Related]  

  • 33. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
    Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
    Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
    Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
    BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial.
    Liu Y; Zheng Z; Li M; Zhang Y; Zhao F; Gong H; Lin H; Huang W; Chen X; Xu Z; Li X; Liu W; Cui Y; Zheng A; Li B
    Int J Cancer; 2022 Aug; 151(4):607-615. PubMed ID: 35419831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
    Chen MQ; Lin QL; Chen YG; Guo JH; Xu BH; Tian Y
    J Chin Med Assoc; 2017 Oct; 80(10):636-643. PubMed ID: 28716602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.